About Professor Michael Murray

Michael Murray's research has focused on the function and regulation of the cytochrome P450 (CYP) enzymes in humans and their roles in disease progression. CYPs mediate the biotransformation of drugs and endobiotics. From this work we have recently developed analogues of CYP-derived fatty acid metabolites as novel anticancer drugs and have also found that over-expression of CYPs in human cancers promotes the development of drug resistance.

Research in this laboratory uses modern cellular and molecular methods to define human gene regulation and expression. Recent papers have reported signaling mechanisms that control the actions of drugs and endobiotics on gene expression. Using analytical methods such as liquid chromatography tandem-mass spectrometry we have defined enzymic biotransformation pathways in human tissues and cells. Identification of fatty acid metabolites that suppress cancer cell proliferation has led to the design of novel anticancer agents. Synthetic organic chemistry has been used to produce these agents for evaluation in cell-based and in vivo animal assays. The structural basis for drug candidate optimization has been established by computational chemistry to develop pharmacophoric models.

Michael Murray is Professor in the Pharmacogenomics and Drug Development Group in the Discipline of Pharmacology, School of Medical Sciences, Sydney Medical School, at the University of Sydney (located in the Medical Foundation Building). He graduated in Pharmacy from that University in 1978, completed a PhD in 1982 and was awarded a DSc in 1996. He was appointed to the NHMRC Research Fellowship scheme in 1987 and remained within the scheme until 1998 when he took up an academic position. In 2003 he returned to the University of Sydney to the Chair of Pharmacogenomics. He has conducted research in the CYP field since 1978, beginning with the synthesis and structure-activity evaluation of CYP inhibitors, before moving to the mechanisms of clinically significant inhibitory drug interactions involving CYPs. Studies of CYP dysregulation in disease and altered nutritional states have led to recent work on the molecular regulation of CYP genes. He is the author of over 180 original papers and reviews to date and has been an invited participant at a number of national and international meetings. He has presented invited symposia or chaired sessions at several recent international meetings in the UK, Czech Republic, Canada, Puerto Rico, USA, Thailand and Australia. These presentations discussed the role of CYPs in apoptotic cell death, translational medicine and the progression of cancer and other diseases. He has been a contributor to the scientific activities of a number of societies, as a councillor and member of Research Committees. He presently serves on the editorial boards of Xenobiotica and Toxicology and Applied Pharmacology.

Selected publications

    * PH Cui, T Rawling, TB Gillani, K Bourget, XS Wang, F Zhou and M Murray. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells. Biochem Pharmacol PubMedId: 23732299
    * PH Cui, T Rawling, K Bourget, T Kim, CC Duke, MR Doddareddy, DE Hibbs, F Zhou, BN Tattam, N Petrovic and M Murray. Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2. J Med Chem 55, 7163-7172 (2012). PubMedId: 22822908
    * PH Cui, N Petrovic and M Murray. The -3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 downregulation. Brit J Pharmacol 162, 1143-1155 (2011). PubMedId: 21077851
    * N Nebot, S Crettol, F d'Esposito, B Tattam, DE Hibbs and M Murray. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Brit J Pharmacol 161, 1059-1069 (2010) PubMedId: 20977456
    * AC Lee and M Murray. Upregulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2. Mol Pharmacol 77, 987-994 (2010). PubMedId: 20194533
    * S Crettol, N Petrovic and M Murray. Pharmacogenetics of phase I and phase II drug metabolism. Current Pharm Design 16, 204-219 (2010). PubMedId: 19835560
    * M Szymczak, M Murray and N Petrovic. Modulation of angiogenesis by -3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 111, 3514-3521 (2008) PubMedId: 18216296
    * NY Marden and M Murray. Characterization of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. Biochemical Journal 391, 631-640 (2005) PubMedId: 16008525
    * NY Marden, E Fiala-Beer, SH Xiang and M Murray. Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochemical Journal 373, 669-680 (2003) PubMedId: 12737630
    * M Murray. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics 23, 132-146 (1992) PubMedId: 1511529
    * M Murray M and GF Reidy. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacological Reviews 42, 85-101 (1990) PubMedId: 2198606